year 18, Issue 2 (March - April 2024)                   Iran J Med Microbiol 2024, 18(2): 6-6 | Back to browse issues page

XML Persian Abstract Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Amirmozafari N, Haddadi A, Mirnejad R, Angaji S A, Babapour E. Relationship Between Drug Efflux Pumps and Resistance to Ciprofloxacin in Clinical Isolates of Acinetobacter baumannii. Iran J Med Microbiol 2024; 18 (2) :6-6
URL: http://ijmm.ir/article-1-2327-en.html
1- Microbiology Department, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
2- Department of Microbiology, Karaj Branch, Islamic Azad University, Karaj, Iran
3- Molecular Biology Research Center, Systems Biology and Poisonings Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran
4- Department of Cell and Molecular Biology, Faculty of Biological Sciences, Kharazmi University, Tehran, Iran
5- Department of Microbiology, Karaj Branch, Islamic Azad University, Karaj, Iran , e.babapour@kiau.ac.ir
Abstract:   (207 Views)

Background and Aim: Acinetobacter baumannii (A. baumannii) is an important bacterium that can cause multidrug-resistant nosocomial infections in patients who are admitted to different hospital wards. Various factors play role in resistance of this bacterium to antibiotics, one of the most important of which is the presence of drug efflux pumps. This study aimed to investigate the presence of the AdeABC efflux system and its role in drug resistance by inactivating them.
Materials & Methods: For this purpose, clinical samples were collected from three hospitals in Tehran, Iran for one year. By culture and biochemical methods, the initial diagnosis was made for the identification of A. baumannii. At last, through a molecular method, the identified prototypes were confirmed. To investigate the role of antibiotic efflux pump in drug resistance, minimum inhibitory concentration (MIC) for ciprofloxacin in the presence and absence of an efflux pump inhibitor, carbonyl cyanide 3-chlorophenylhy­drazone (CCCP), was determined by microdilution method. Additionally, the presence of adeB, adeR, and adeS genes related to the AdeABC depletion system was investigated by PCR.
Results: The results showed that more than 98% of the isolated bacteria had adeB, adeR, and adeS genes in the AdeABC depletion system. Approximately 47.18% of these bacteria displayed a fourfold reduction in ciprofloxacin MIC levels in the presence of CCCP.
Conclusion:  Administration of a suitable antibiotic along with a safe efflux pump inhibitor for the treatment of A. baumannii infections can help to reduce material and spiritual damages caused by resistant bacteria

     
Type of Study: Original Research Article | Subject: Antibiotic Resistance
Received: 2024/02/14 | Accepted: 2024/05/15 | ePublished: 2024/05/25

References
1. Babapour E, Haddadi A, Mirnejad R, Angaji S-A, Amirmozafari N. Biofilm formation in clinical isolates of nosocomial Acinetobacter baumannii and its relationship with multidrug resistance. Asian Pac J Trop. 2016; 6(6):528-33. [DOI:10.1016/j.apjtb.2016.04.006]
2. Smith T, Rana RS, Missiaen P, Rose KD, Sahni A, Singh H, et al. High bat (Chiroptera) diversity in the Early Eocene of India. Naturwissenschaften. 2007;94:1003-9. [DOI:10.1007/s00114-007-0280-9] [PMID]
3. Rodríguez-Baño J, Cisneros JM, Fernández-Cuenca F, Ribera A, Vila J, Pascual A, et al. Clinical features and epidemiology of Acinetobacter baumannii colonization and infection in Spanish hospitals. Infect Control Hosp Epidemiol. 2004;25(10):819-24. [DOI:10.1086/502302] [PMID]
4. Kim UJ, Kim HK, An JH, Cho SK, Park K-H, Jang H-C. Update on the epidemiology, treatment, and outcomes of carbapenem-resistant Acinetobacter infections. Chonnam Med J. 2014;50(2):37-44. [DOI:10.4068/cmj.2014.50.2.37] [PMID] [PMCID]
5. Sugawara E, Nikaido H. Properties of AdeABC and AdeIJK efflux systems of Acinetobacter baumannii compared with those of the AcrAB-TolC system of Escherichia coli. Antimicrob. Agents Chemother. 2014;58(12):7250-7. [DOI:10.1128/AAC.03728-14] [PMID] [PMCID]
6. Giles SK, Stroeher UH, Eijkelkamp BA, Brown MH. Identification of genes essential for pellicle formation in Acinetobacter baumannii. BMC Microbiol. 2015;15(1):1-14. [DOI:10.1186/s12866-015-0440-6] [PMID] [PMCID]
7. Bayram Y, Parlak M, Aypak C, Bayram İ. Three-year review of bacteriological profile and antibiogram of burn wound isolates in Van, Turkey. Int JMed Sci. 2013;10(1):19. [DOI:10.7150/ijms.4723] [PMID] [PMCID]
8. Falagas ME, Rafailidis PI. Attributable mortality of Acinetobacter baumannii: no longer a controversial issue. Critical Care.2007;11(3):134. [DOI:10.1186/cc5911] [PMID] [PMCID]
9. Valentine SC, Contreras D, Tan S, Real LJ, Chu S, Xu HH. Phenotypic and molecular characterization of Acinetobacter baumannii clinical isolates from nosocomial outbreaks in Los Angeles County, California. J Clin Microbiol. 2008;46(8):2499-507. [DOI:10.1128/JCM.00367-08] [PMID] [PMCID]
10. Wieczorek P, Sacha P, Hauschild T, Zórawski M, Krawczyk M, Tryniszewska E. Multidrug resistant Acinetobacter baumannii--the role of AdeABC (RND family) efflux pump in resistance to antibiotics. Folia Histochemica et cyto Biologica. 2008;46(3):257-67. [DOI:10.2478/v10042-008-0056-x] [PMID]
11. Sengupta S, Kumar P, Ciraj A, Shivananda P. Acinetobacter baumannii an emerging nosocomial pathogen in the burns unit Manipal, India. Burns. 2001;27(2):140-4. [DOI:10.1016/S0305-4179(00)00094-2] [PMID]
12. Joly-Guillou ML. Clinical impact and pathogenicity of Acinetobacter. Clin Microbiol Infect. 2005;11(11):868-73. [DOI:10.1111/j.1469-0691.2005.01227.x] [PMID]
13. Fournier P-E, Vallenet D, Barbe V, Audic S, Ogata H, Poirel L, et al. Comparative genomics of multidrug resistance in Acinetobacter baumannii. PLoS Genet. 2006;2(1):e7. [DOI:10.1371/journal.pgen.0020007] [PMID] [PMCID]
14. Neonakis IK, Spandidos DA, Petinaki E. Confronting multidrug-resistant Acinetobacter baumannii: a review. Int J Antimicrob Agents. 2011;37(2):102-9. [DOI:10.1016/j.ijantimicag.2010.10.014] [PMID]
15. Rahbar M, Mehrgan H, Aliakbari NH. Prevalence of antibiotic-resistant Acinetobacter baumannii in a 1000-bed tertiary care hospital in Tehran, Iran. Indian J Pathol Microbiol. 2010; 53(2):290-3. [DOI:10.4103/0377-4929.64333] [PMID]
16. Armin S, Karimi A, Fallah F, Tabatabaii SR, Alfatemi SM, Khiabanirad P, et al. Antimicrobial resistance patterns of Acinetobacter baumannii, Pseudomonas aeruginosa and Staphylococcus aureus isolated from patients with nosocomial infections admitted to tehran hospitals. Arch Pediatr Infect Dis. 2015;3(4):e32554 [DOI:10.5812/pedinfect.32554]
17. Mirnejad R, Mostofi S, Masjedian F. Antibiotic resistance and carriage class 1 and 2 integrons in clinical isolates of Acinetobacter baumannii from Tehran, Iran. Asian Pac J Trop. 2013;3(2):140-5. [DOI:10.1016/S2221-1691(13)60038-6] [PMID]
18. Aminzadeh Z and Yaghubi T. Drug-resistant post-neurosurgical nosocomial Acinetobacter baumannii meningitis in two Iranian hospitals. African J Microbiol Res. 2012;11(17):4083-84. [DOI:10.5897/AJB11.3850]
19. Peymani A, Fargnia S, Nahaei MR, Sohrabi N, Abbasi L, Ansarin K, et al. Prevalence of class I integron multidrug-resistant Acinetobacter baumannii in Tabriz, northwest of Iran. Pol J Microbiol. 2012;61(1):57-60. [DOI:10.33073/pjm-2012-007] [PMID]
20. Basatian-Tashkan B, Niakan M, Khaledi M, Afkhami H, Sameni F, Bakhti S, et al. Antibiotic resistance assessment of Acinetobacter baumannii isolates from Tehran hospitals due to the presence of efflux pumps encoding genes (adeA and adeS genes) by molecular method. BMC Res Notes. 2020;13:1-6. [DOI:10.1186/s13104-020-05387-6] [PMID] [PMCID]
21. Mahmoudi H, Zare Fahim N, Alikhani M Y, Shokoohizadeh L. Investigation of Antimicrobial Effect of Berberine on Ciprofloxacin and Imipenem Resistance Acinetobacter baumannii Isolated from Hamadan Hospitals. Iran J Med Microbiol. 2020;14(1):44-54. [DOI:10.30699/ijmm.14.1.44]
22. Ghajavand H, Esfahani BN, Havaei SA, Moghim S, Fazeli H. Molecular identification of Acinetobacter baumannii isolated from intensive care units and their antimicrobial resistance patterns. Adv Biomed Res. 2015;4(1):110. [DOI:10.4103/2277-9175.157826] [PMID] [PMCID]
23. Baran G, Erbay A, Bodur H, Öngürü P, Akıncı E, Balaban N, et al. Risk factors for nosocomial imipenem-resistant Acinetobacter baumannii infections. Int J Infect Dis. 2008;12(1):16-21. [DOI:10.1016/j.ijid.2007.03.005] [PMID]
24. Ardebili A, Lari AR, Talebi M. Correlation of ciprofloxacin resistance with the AdeABC efflux system in Acinetobacter baumannii clinical isolates. Ann Lab Med. 2014;34(6):433-8. [DOI:10.3343/alm.2014.34.6.433] [PMID] [PMCID]
25. Park S, Lee KM, Yoo YS, Yoo JS, Yoo JI, Kim HS, et al. Alterations of gyrA, gyrB, and parC and activity of efflux pump in fluoroquinolone-resistant Acinetobacter baumannii. Osong Public Health Res Perspect. 2011;2(3):164-70. [DOI:10.1016/j.phrp.2011.11.040] [PMID] [PMCID]
26. Srinivasan VB, Rajamohan G, Pancholi P, Stevenson K, Tadesse D, Patchanee P, et al. Genetic relatedness and molecular characterization of multidrug-resistant Acinetobacter baumannii isolated in central Ohio, USA. Ann Clin Microbiol Antimicrob. 2009;8(1):21. [DOI:10.1186/1476-0711-8-21] [PMID] [PMCID]
27. Chopra S, Galande A. A fluoroquinolone-resistant Acinetobacter baumannii without the quinolone resistance-determining region mutations. J Antimicrob Chemother. 2011;66(11):2668-70. [DOI:10.1093/jac/dkr364] [PMID]
28. Eliopoulos GM, Maragakis LL, Perl TM. Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options. Clin Infect Dis. 2008;46(8):1254-63. [DOI:10.1086/529198] [PMID]
29. Sun J-R, Chan M-C, Chang T-Y, Wang W-Y, Chiueh T-S. Overexpression of the adeB gene in clinical isolates of tigecycline-nonsusceptible Acinetobacter baumannii without insertion mutations in adeRS. Antimicrob Agents Chemother. 2010;54(11):4934-8. [DOI:10.1128/AAC.00414-10] [PMID] [PMCID]
30. Bratu S, Landman D, Martin DA, Georgescu C, Quale J. Correlation of antimicrobial resistance with β-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. Antimicrob Agents Chemother. 2008; 52(9):2999-3005. [DOI:10.1128/AAC.01684-07] [PMID] [PMCID]
31. Nemec A, Maixnerová M, van der Reijden TJ, Van den Broek PJ, Dijkshoorn L. Relationship between the AdeABC efflux system gene content, netilmicin susceptibility and multidrug resistance in a genotypically diverse collection of Acinetobacter baumannii strains. J Antimicrob Chemother. 2007;60(3):483-9. [DOI:10.1093/jac/dkm231] [PMID]
32. Huys G, Cnockaert M, Vaneechoutte M, Woodford N, Nemec A, Dijkshoorn L, et al. Distribution of tetracycline resistance genes in genotypically related and unrelated multiresistant Acinetobacter baumannii strains from different European hospitals. Res Microbiol. 2005;156(3):348-55. [DOI:10.1016/j.resmic.2004.10.008] [PMID]
33. Abdi-Ali A, Nikasa P, Rahmani-Badi A, Al-Hamad A. In vitro Evaluation of proton motive force-dependent efflux pumps among multidrug-resistant Acinetobacter baumannii isolated from patients at Tehran hospitals. Jundishapur J Microbiol. 2013;6(7):1-5. [DOI:10.5812/jjm.6792]
34. Huang L, Sun L, Xu G, Xia T. Differential susceptibility to carbapenems due to the AdeABC efflux pump among nosocomial outbreak isolates of Acinetobacter baumannii in a Chinese hospital. Diagn Microbiol Infect Dis. 2008;62(3):326-32 [DOI:10.1016/j.diagmicrobio.2008.06.008] [PMID]

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY-NC 4.0 | Iranian Journal of Medical Microbiology

Designed & Developed by : Yektaweb | Publisher: Farname Inc